INT66485

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 2
Total Number 2
Disease Relevance 1.27
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Pah)
Anatomy Link Frequency
heart 2
Pah (Mus musculus)
Pain Link Frequency Relevance Heat
Enkephalin 3 99.52 Very High Very High Very High
Opioid 3 98.24 Very High Very High Very High
mu opioid receptor 2 95.84 Very High Very High Very High
Inflammatory mediators 1 90.24 High High
opioid receptor 1 89.76 High High
Calcium channel 2 83.88 Quite High
Antinociceptive 1 76.44 Quite High
antagonist 5 75.00 Quite High
MU agonist 1 75.00 Quite High
tail-flick 3 45.68 Quite Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 66 100.00 Very High Very High Very High
Disease 17 99.18 Very High Very High Very High
Apoptosis 2 92.56 High High
Hyperplasia 1 92.00 High High
INFLAMMATION 1 89.84 High High
Cv General 4 Under Development 22 88.64 High High
Reprotox - General 2 5 63.20 Quite High
Hemoglobinopathy 1 59.88 Quite High
Schistosomiasis 1 55.56 Quite High
Hypertension 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These key pathways currently serve as targets for disease-specific treatment modalities that have revolutionized PAH management, by improving functional capacity, hemodynamics, and patient well being.5 In PAH, the ideal pharmacologic agents should facilitate vasorelaxation and restoration of the balance between apoptosis and cellular proliferation, ultimately preserving RV function and delaying the onset of right heart failure.6
Negative_regulation (revolutionized) of PAH Binding (management) of in heart associated with pulmonary hypertension, cv general 4 under development, apoptosis, disease and hyperplasia
1) Confidence 0.35 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.27 Pain Relevance 0.09
Incubation of membranes with N-CBM-TAMO resulted in wash-resistant inhibition of the binding of the mu-selective peptide [3H][D-Ala2,(Me)Phe4, Gly(ol)5]-enkephalin, the kappa-selective opioid [3H]U69,593 ((trans)-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzenacetamide+ ++ methanesulfonate hydrate)) and, to a lesser extent, the delta-selective peptide [D-Pen2, p-Cl-phenylalanine4, D-Pen5]enkephalin.
Negative_regulation (inhibition) of Phe4 Binding (binding) of associated with enkephalin and opioid
2) Confidence 0.01 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8930155 Disease Relevance 0 Pain Relevance 0.75

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox